Lilly Expands Biotech Capabilities to Match Expanding Biotech Pipeline
First phase of $560 million complex completed
At a ceremony at its Indianapolis operations, company officials dedicated a state-of-the-art bioproducts pilot manufacturing plant that shall help the company bring advanced biotech medicines to patients through more efficient, productive and dependable manufacturing processes. The company also announced the opening of a research support facility, into which 700 scientists, engineers and support staff will relocate.
Lilly initially announced plans for the biotechnology complex in 2002. In 2004, those plans were expanded to nearly twice their original size to better meet the company's pipeline of biotech drugs.
"Inside these new buildings, the latest in highly sophisticated technologies and equipment for conducting biotech research and development have been incorporated," said Steven Paul, M.D., Lilly's executive vice president of science and technology. "Taken together -- the facilities, the technologies, and an interdisciplinary approach -- we've created a new model for Lilly that gives the company a competitive advantage in bringing breakthrough medicines to patients in a more efficient, productive, and dependable manner."
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.